You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas - 2021
Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-02-03
Feb 3, 2022
U
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma - 2021
Completed
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • London, United Kingdom
    University College London Hospital
2021-10-01
Oct 1, 2021
S
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
2021-09-20
Sep 20, 2021
N
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas - 2022
Completed
  • Lymphoma, Large-Cell, Anaplasitc
  • +4 more
  • Anti-CD30-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022
N
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
P
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
Not yet recruiting
  • T-cell Lymphoma
  • Tucidinostat, Azacitidine combined with CHOP
  • (no location specified)
2021-10-09
Oct 9, 2021
L
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
2022-02-15
Feb 15, 2022
F
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Recruiting
  • Cutaneous T-cell Lymphoma (CTCL)
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
2022-02-02
Feb 2, 2022
T
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-12-21
Dec 21, 2021
M
Diagnostic Classifier for Cutaneous T-cell Lymphomas
Recruiting
  • CTCL/ Mycosis Fungoides
  • Skin suction blistering and skin biopsies
  • Vienna, Austria
    Medical University of Vienna
2022-04-04
Apr 4, 2022
M
CAR-37 T Cells In Hematologic Malignancies
Recruiting
  • Hematologic Malignancy
  • +5 more
  • CAR-37 T cells
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
2021-10-28
Oct 28, 2021
H
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021
O
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
2022-02-21
Feb 21, 2022
F
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
2021-12-03
Dec 3, 2021
N
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Not yet recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
2022-01-24
Jan 24, 2022
P
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Not yet recruiting
  • T-cell Non-Hodgkin's Lymphoma
  • CD147- CAR T cells
  • (no location specified)
2021-08-18
Aug 18, 2021
K
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +4 more
  • Cincinnati, Ohio
    The Christ Hospital Cancer Center
2022-02-08
Feb 8, 2022
N
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
S
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Not yet recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • (no location specified)
2022-03-18
Mar 18, 2022
T
Pembrolizumab and Brentuximab Vedotin in Patients With Relapsed/Refractory T-cell Lymphoma
Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
2022-03-28
Mar 28, 2022
C
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Recruiting
  • Lymphoma, T-Cell, Peripheral
  • Osaka, Japan
    Nihon Seimei Hospital
2021-06-01
Jun 1, 2021
N
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Active, not recruiting
  • Peripheral T-cell Lymphoma NOS
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-02-02
Feb 2, 2022
C
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma - 2012
Terminated
  • Cutaneous T-cell Lymphoma (CTCL)
  • Stanford, California
  • +2 more
2021-12-07
Dec 7, 2021
W
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
2022-02-14
Feb 14, 2022
U
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Recruiting
  • Lymphoma, T-Cell
  • Charlottesville, Virginia
    University of Virginia
2022-03-16
Mar 16, 2022